April 2018
Volume 4, Issue 5
This issue features a look at the U.S. health-care system’s transition from a paper-based system to electronic health records, an introduction to a series about oncology nurse practitioners, and more.
Table of Contents
April 2018 Issue
Strengthening the Role of the Oncology Nurse Practitioner
In this edition, Catherine Bishop, DNP, NP, introduces a series of articles about issues affecting oncology nurse practitioners. Here, Dr. Bishop describes how these...
Updates to Our Style Guide for the Sartorially Challenged
Every so often, the crackerjack editorial team of ASH Clinical News gets together and discusses style.
No, not of the sartorial variety, particularly as mine...
April 2018 Issue
Remembering Ihor R. Lemischka and Günter Blobel, Feinstein Institute Researcher Awarded NIH Grant, and...
Remembering Ihor R. Lemischka (1953-2017)
Ihor R. Lemischka, PhD, a pioneer in the fields of hematopoiesis and pluripotent cell biology, died on December 17, 2017.Dr....
Roundtable Discussion With Senator Booker, The Hematologist App Now Available, and more
ASH Participates in Roundtable Discussion With Senator Booker
On February 28, Sens. Tim Scott (R-SC) and Cory Booker (D-NJ) introduced the Sickle Cell Disease...
April 2018 Issue
Pulling Back the Curtain: Olatoyosi Odenike, MD
In this edition, Olatoyosi Odenike, MD, speaks about her “rebellious” path to medical school in Nigeria, the importance of life’s tangents, and her passion...
Are EHRs and Physicians Out of Sync?
In the past decade, the U.S. health-care system has undergone a historic transformation from a paper-based system to electronic health records (EHRs), which –...
April 2018 Issue
FDA Examining Patient Deaths Associated With Extracorporeal Photopheresis Treatment
The FDA published a letter to health-care providers noting that the CELLEX® Photopheresis System is under review following reports of venous thromboembolism (VTE), including...
FDA Puts Clinical Hold on BPX-501 After Patients Develop Encephalopathy
The FDA put a clinical hold on the investigational cellular immunotherapy BPX-501, halting four U.S. studies assessing the drug’s use for cancer and orphan-inherited...
Employer-Sponsored Health-Care Spending Rises to Highest Point in 2016
According to an annual report by the Health Care Cost Institute (HCCI), employer-sponsored health-care spending increased to the highest point in 2016, mainly because...
ACA Reduced Out-of-Pocket Spending, Study Finds
A study published in JAMA Internal Medicine found that the implementation of the Affordable Care Act (ACA) was associated with reduced out-of-pocket spending, although...
Obesity Influences Hematopoietic Stem Cell Health
According to research published in the Journal of Experimental Medicine, obesity affects the long-term health of hematopoietic stem cells (HSCs). The researchers said their...
Legislation to Improve SCD Data Collection and Care Moves Through Congress
On February 28, Sens. Tim Scott (R-SC) and Cory Booker (D-NJ) introduced the Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018. This...
The Effect of Moxetumomab Pasudotox on Minimal Residual Disease in Hairy Cell Leukemia
Nearly two-thirds of patients with relapsed/refractory hairy cell leukemia (HCL) who were treated with the anti-CD22 recombinant immunotoxin moxetumomab pasudotox achieved complete remission (CR),...
Report Finds Drug Discounts to Insurers Continue to Rise
Analysts found that the average sale, rebate, and allowance offered to insurers for prescription medications increased from 28 percent in 2012 to 41 percent...
FDA Expands Approval of Ferumoxytol Injection for Iron Deficiency Anemia
The FDA approved a supplemental new drug application for ferumoxytol injection to include all eligible adults with iron-deficiency anemia (IDA) who cannot tolerate or...
Multiple Myeloma Outcomes Differ Based on Socioeconomic Factors
Despite the gains made in improving treatment for and care of patients with multiple myeloma (MM), disparities persist based on race and socioeconomic status....
Weighing the Global Cancer Burden: CONCORD-3 Finds Cancer Survival Varies by Location
Five-year cancer survival rates are increasing globally, but disparities exist between regions, according to results from the CONCORD-3 global cancer surveillance program published in...
Aspirin as Effective as Rivaroxaban for Preventing VTE After Total Hip or Knee Arthroplasty
Standard aspirin is as effective as the newer, direct oral anticoagulant (DOAC) rivaroxaban for preventing venous thromboembolism (VTE) in patients who have undergone total...
DOACs Versus Warfarin in Patients With Cancer and Atrial Fibrillation
Newer direct oral anticoagulants (DOACs) offer an effective alternative to warfarin that does not require monitoring, but these agents are often not recommended in...
First-in-Human Trial Finds Single-Agent, Post-Transplant IL-15 Superagonist Tolerable, Effective
Allogeneic hematopoietic cell transplantation (alloHCT) is primary potentially curative option for certain patients with advanced hematologic malignancies, but disease relapse post-transplant remains a major...
Five-Year Follow-Up Shows Response to Ibrutinib Deepens Over Time for CLL Patients
Treatment with continuous, single-agent ibrutinib led to durable responses in patients with chronic lymphocytic leukemia (CLL), even among previously untreated patients, patients older than...
April 2018 Issue
How would you treat a patient with the C282Y mutation and a family history...
This month, Susan F. Leitman, MD, discusses managing a patient with the C282Y mutation and a family history of hemochromatosis.
And don't forget to check...
How I Treat In Brief: Type 2B von Willebrand Disease
This month, Rebecca Kruse-Jarres, MD, MPH, and Jill M. Johnsen, MD, discuss the diagnosis and treatment of patients with type 2B von Willebrand disease...
